Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial is a research paper published in Journal of Clinical Oncology (2022). On theSindex it has a DataRank of 3.3. It has been cited 100 times, with 94 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.692
From this paper's citation signal
Citation Network Contribution
2.6
From 76 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 94 citers.
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: R25 CA068647
NCI NIH HHS
Grant: T32 CA082088
NCI NIH HHS
Grant: P50 CA221745
NCATS NIH HHS
Grant: UL1 TR002384
National Institutes of Health
Grant: 2R25CA068647-14
Methods in Clinical Cancer Research Workshop
National Institutes of Health
Grant: 1P50CA221745-01A1
SPORE in Bladder Cancer
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals